Next Phase Newsletter

A US fund invests in early-stage startups in many industries with a preference for biotech and IT technology. Typical equity investment size ranges from US$0.5-2 million in Seed to Series B stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 5+ deals in the next 12 months and can invest globally with a focus on the US.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in disease-modification therapies, diagnostics and medical devices. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office/venture capital firm based in USA manages an evergreen fund that operates free from the constraints of traditional venture capital funds. The firm seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA invests in companies in Consumer, Crypto and Life Sciences & Digital Health. For companies in the life sciences, the firm generally invests in Seed and Series A/B rounds, committing between $1-10M in capital.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, MedTech, digital health, and R&D services. For therapeutics, the firm will consider therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, MedTech, Digital Health, and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services, and care management platforms.

The firm looks for companies with a strong management team, large market opportunities, and disruptive technology. When investing, the firm is willing to lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage venture capital firm is dedicated to building next generation companies in the healthcare sector. The fund is focused on the cell therapy and regenerative medicine sector and will consider opportunities encompassing therapeutics, diagnostics, and those harnessing data to revolutionize the sector. The firm partners with passionate teams that are backed by strong scientific platforms and will primarily invest in preclinical stage assets, contributing $1 – 2M initially. With operations in North America and Asia, the fund take a global approach to building value in their portfolio by linking these two important life science markets and leveraging the respective advantages of each ecosystem.

The firm invests exclusively in technologies relating to cell therapy and regenerative medicine, including precision medicine tools and discovery of new treatment modalities. The company can be in therapeutics, diagnostics or digital health. The firm’s primary areas of interest are oncology, autoimmune disorders, CNS, cardiovascular, renal and liver.

Most of the firm’s investments are in companies either located or looking to enter the Japanese market. The firm can lead or co-invest, and will generally take a board seat when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm under a large conglomerate invests in a wide range of industries including biotech, ICT, media, food, among others. With regards to life sciences and healthcare, The firm generally invests in Series A to B rounds but has participated in as early as pre-Series A. Typical initial size of investment is over $1M, and is subject to larger amounts depending on the stage of the company. The firm has invested mostly in USA and Korea, but is open to considering global opportunities.

The firm will consider opportunities across therapeutics, diagnostics, digital health. Within these sectors, the firm is most interested in drug discovery and development, diagnostics, digital health, and microbiome. In therapeutics, the firm is open to both pre-clinical and clinical assets & platforms and will consider all different types of modalities (small molecule, antibodies, cell/gene therapy). The firm will consider all indications but is interested in large markets including oncology/immuno-oncology and CNS.

The firm has no specific management team requirements. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund of a large holding company looks to provide a unique stepping stone for successful companies to broaden their global reach. The firm offers partners deep understanding of relevant audiences and a unique opportunity for truly innovative, trail-blazing consumer-related digital health ventures. The firm is looking to invest in digital therapeutics, POC diagnostics, and other dHealth companies from seed stage and beyond. The firm is interested in companies with well defined, relevant products and solutions, preferably with initial validation or proof-of-concept. The firm invests globally.

Within the digital health and POC diagnostics space, the firm has many areas of interest. These include, but are not limited to, telemedicine, remote monitoring, patient adherence, FemTech and aging, medication dispensing, digital therapeutics, POC and home diagnostics.

The firm has no specific requirements for company and management team, and makes decisions on a case-by-case basis. The firm can lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based life sciences venture capital and company formation firm with billions of dollars under management is currently investing out of their latest fund that closed last year. The firm will make equity investments of approximately $30–50 million over the lifetime of the company and can either lead investments or co-invest. The firm considers investment opportunities worldwide.

The firm invests primarily in therapeutics and invests broadly across different therapeutic areas and modalities. Areas of high interest include precision medicine approaches, gene therapy, autoimmune diseases, oncology, neurology (particularly diseases with genetically defined populations), ophthalmology, and rare diseases. The firm generally invests from preclinical (2–3 years pre-IND) through to Phase II, and prefers to invest in assets with good animal models and/or genetic evidence to support efficacy and target validation.

The firm generally invests in privately held companies and likes to work with experienced management teams who have had prior startup successes. The firm is an active investor and the partners have deep experience in company building, and we are therefore interested in providing support on strategy, BD, recruiting and other areas of active management in addition to providing capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.